HER2 testing in breast carcinoma: Very low concordance rate between reference and local laboratories in Brazil

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 2, 2011, Pages 112-118

  Wludarski, Sheila Cristina Lordelo ^a,b   Lopes, Lisandro Ferreira ^a   Berto E Silva, Tácio R ^a   Carvalho, Filomena M ^b   Weiss, Lawrence M ^c   Bacchi, Carlos E ^a,b  

^a Consultoria em Patologia ^*  (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Brazil; HER2; immunohistochemistry; local laboratory; reference laboratory

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

APOCRINE CARCINOMA; ARTICLE; ASSAY; BIOGEOGRAPHIC REGION; BRAZIL; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER INVASION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM; STANDARDIZATION; THERAPEUTIC ERROR; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; BRAZIL; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; RECEPTOR, ERBB-2; REFERENCE STANDARDS; TUMOR MARKERS, BIOLOGICAL;

EID: 79951942570     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181f0b044     Document Type: Article

References (56)

1. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:13-59.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/ neu oncogene. Science. 1987;235:177-182. (Pubitemid 17231334)
3. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61(suppl 2):1-13. (Pubitemid 33033419)
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137. (Pubitemid 33674041)
5. Ross JS, Fletcher JA. HER2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(1 suppl 1):S53-S67. (Pubitemid 30219464)
6. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118-121.
7. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648. (Pubitemid 29415219)
8. Fornier M, Esteva FJ, Seudman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol. 2000;27(6 suppl 11):38-45; discussion 92-100. (Pubitemid 32172255)
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
10. Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004;22: 1071-1077. (Pubitemid 41095040)
11. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol. 2002;20: 719-726. (Pubitemid 34111379)
12. Ross JS, Slodkowska EA, Symmans WF, et al. The HER2 receptor and breast cancer: ten years of targeted anti-HER2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
13. Persons DL, Tubbs RR, Cooley LD, et al. HER2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med. 2006;130:325-331.
14. Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true HER2/neu gene amplification status in breast cancer. Mol Cancer Ther. 2006; 5:2572-2579. (Pubitemid 44650922)
15. Barron JJ, Cziraky MJ, Weisman T, et al. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist. 2009;14:760-768.
16. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER2/neu in breast cancer. J Clin Oncol. 1999;17:1974-1982. (Pubitemid 29318824)
17. Ridolfi RL, Jamehdor MR, Arber JM. HER2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873. (Pubitemid 30643834)
18. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
19. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154. (Pubitemid 34118890)
20. Leong TY, Leong AS. Controversies in the assessment of HER-2: more questions than answers. Adv Anat Pathol. 2006;13: 263-269. (Pubitemid 44439981)
21. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105. (Pubitemid 34791099)
22. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423. (Pubitemid 36411217)
23. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63-69. (Pubitemid 38821193)
24. Yaziji H, Goldstein LC, Barry TS, et al. HER2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291: 1972-1977. (Pubitemid 38544278)
25. Gancberg D, Lespagnard L, Rouas G, et al. Sensitivity of HER-2/ neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol. 2000;113:675-682. (Pubitemid 33044308)
26. Vera-Román JM, Rubio-Martínez LA. Comparative assays for the HER2/neu oncogene status in breast cancer. Arch Pathol Lab Med. 2004;128:627-633. (Pubitemid 41490421)
27. Ainsworth R, Bartlett JM, Going JJ, et al. IHC for HER2 with CBE356 antibody is a more accurate predictor of HER2 gene amplification by FISH than HercepTest in breast carcinoma. J Clin Pathol. 2005;58:1086-1090. (Pubitemid 41416060)
28. Kulka J, Tôké s AM, Kaposi-Novák P, et al. Detection of HER2/neu gene amplification in breast carcinomas using quantitative real-time PCR: a comparison with immunohistochemical and FISH results. Pathol Oncol Res. 2006;12:197-204.
29. Rossi E, Ubiali A, Cadei M, et al. HER2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH). Appl Immunohistochem Mol Morphol. 2006;14:127-131. (Pubitemid 43941173)
30. Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007;15:94-102. (Pubitemid 46673324)
31. Van der Vegt B, de Bock GH, Bart J, et al. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod Pathol. 2009;22:879-886.
32. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675. (Pubitemid 32708634)
33. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21:1271-1277.
34. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777. (Pubitemid 24173773)
35. Ellis IO, Bartlett J, Dowsett M, et al. Best practice n1 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004; 57:233-237. (Pubitemid 38338829)
36. Hanna W, O'malley FP, Barnes P, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol. 2007;14:149-153.
37. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
38. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182. (Pubitemid 36245750)
39. Zarbo RJ, HammondME. HER2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003;127:549-553.
40. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(suppl 2) S8-S15. (Pubitemid 351592775)
41. Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol. 2001;116:806-810. (Pubitemid 33108149)
42. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333.
43. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854. (Pubitemid 34705057)
44. Roche PC, Jenkins RB, Davidson NE, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94:855-857. (Pubitemid 34705058)
45. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598-6607. (Pubitemid 41339000)
46. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032-3038. (Pubitemid 46638937)
47. Reddy JC, Reimann JD, Anderson SM, et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006;7:153-157. (Pubitemid 44044012)
48. O'Malley FP, Thomson T, Julian J, et al. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Arch Pathol Lab Med. 2008;132:61-65.
49. Papadopoulos S, Kouvatseas G, Skarlos D, et al. Comparison of HER2 detection methods between central and regional laboratories in Greece. Clin Breast Cancer. 2007;7:784-790. (Pubitemid 350086123)
50. Wludarski SC, Bacchi CE. High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma. Appl Immunohistochem Mol Morphol. 2008;16:466-470.
51. Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden's Index. Stat Med. 1996;15:969-986.
52. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
53. Goldman L. Quantitative aspects of clinical reasoning. In: Isselbacher KJ, Braunwald E, eds. Harrison's Principles of Internal Medicine. 13th ed. Copenhagen, Denmark: McGraw-Hill; 1994:43-48.
54. Young KD, Lewis RJ. What is confidence? Part 2: detailed definition and determination of confidence intervals. Ann Emerg Med. 1997;30:311-318. (Pubitemid 27371873)
55. Instituto Brasileiro de Geografia e Estatística web site. Available at: http://www.ibge.gov.br/english. [Accessed February 23, 2010].
56. Estimativa 2010 - Incidência de câncer no Brasil. [Instituto Nacional de Câncer web site]. Available at: http://www1.inca.gov.br/ estimativa/ 2010/index.asp?link=conteudo-view.asp&ID=5. [Accessed February 23, 2010].